ASSESSING CLINICAL EFFICACY AND TRIAL DESIGN PARAMETERS FOR TREATMENTS OF NON-ALCOHOLIC FATTY LIVER DISEASE USING A NOVEL QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL.

被引：0
|
作者：
Rieger, T. R. [1 ]
Allen, R. J. [1 ]
Musante, C. J. [1 ]
机构：
[1] Pfizer Inc, Cambridge, MA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
QSP-014
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [1] ASSESSING CLINICAL EFFICACY AND TRIAL DESIGN PARAMETERS FOR TREATMENTS OF NON-ALCOHOLIC FATTY LIVER DISEASE USING A NOVEL QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL.
    Rieger, T. R.
    Allen, R. J.
    Musante, C. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S110 - S110
  • [2] A Quantitative Systems Pharmacology Model of Liver Lipid Metabolism for Investigation of Non-Alcoholic Fatty Liver Disease
    Rieger, Theodore R.
    Allen, Richard J.
    Musante, Cynthia J.
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [3] A Quantitative Systems Pharmacology Model of Liver Lipid Metabolism for Investigation of Non-Alcoholic Fatty Liver Disease
    Rieger, Theodore R.
    Allen, Richard J.
    Musante, Cynthia J.
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [4] Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design
    Allen, Alina M.
    Therneau, Terry M.
    Ahmed, Omar T.
    Gidener, Tolga
    Mara, Kristin C.
    Larson, Joseph J.
    Canning, Rachel E.
    Benson, Joanne T.
    Kamath, Patrick S.
    JOURNAL OF HEPATOLOGY, 2022, 77 (05) : 1237 - 1245
  • [5] Diagnostic Performance of Quantitative Ultrasound Parameters in Non-alcoholic Fatty Liver Disease
    Torkzaban, Mehnoosh
    Wessner, Corinne E.
    Halegoua-DeMarzio, Dina
    Lyshchik, Andrej
    Nam, Kibo
    ACADEMIC RADIOLOGY, 2024, 31 (01) : 199 - 211
  • [6] Non-alcoholic fatty liver disease: Benchmarking a novel clinical pathway
    Christmas, M.
    Bergin, A.
    Tan, L.
    Ding, Y.
    Khaing, M. M.
    Lin, L.
    Chang, X.
    Thompson, H.
    Rahman, T.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 87 - 88
  • [7] Quantitative succinylome analysis in the liver of non-alcoholic fatty liver disease rat model
    Yang Cheng
    Tianlu Hou
    Jian Ping
    Gaofeng Chen
    Jianjie Chen
    Proteome Science, 14
  • [8] Quantitative succinylome analysis in the liver of non-alcoholic fatty liver disease rat model
    Cheng, Yang
    Hou, Tianlu
    Ping, Jian
    Chen, Gaofeng
    Chen, Jianjie
    PROTEOME SCIENCE, 2016, 14
  • [9] Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease
    Beaton, M. D.
    Chakrabarti, S.
    Levstik, M.
    Speechley, M.
    Marotta, P.
    Adams, P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 37 (07) : 720 - 729
  • [10] Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments
    E. Scorletti
    P. C. Calder
    C. D. Byrne
    Endocrine, 2011, 40 : 332 - 343
12345